DK0960107T3 - 6-Thiosubstituerede paclitaxeler - Google Patents

6-Thiosubstituerede paclitaxeler

Info

Publication number
DK0960107T3
DK0960107T3 DK97954044T DK97954044T DK0960107T3 DK 0960107 T3 DK0960107 T3 DK 0960107T3 DK 97954044 T DK97954044 T DK 97954044T DK 97954044 T DK97954044 T DK 97954044T DK 0960107 T3 DK0960107 T3 DK 0960107T3
Authority
DK
Denmark
Prior art keywords
thiosubstituted
paclitaxels
present
invention concerns
pharmaceutical formulations
Prior art date
Application number
DK97954044T
Other languages
Danish (da)
English (en)
Inventor
Andrew J Staab
John F Kadow
Dolatrai M Vyas
Mark D Wittman
Harold A Mastalerz
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK0960107T3 publication Critical patent/DK0960107T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DK97954044T 1996-12-24 1997-12-05 6-Thiosubstituerede paclitaxeler DK0960107T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3341996P 1996-12-24 1996-12-24
US3635197P 1997-01-23 1997-01-23
PCT/US1997/022152 WO1998028288A1 (en) 1996-12-24 1997-12-05 6-thio-substituted paclitaxels

Publications (1)

Publication Number Publication Date
DK0960107T3 true DK0960107T3 (da) 2003-02-10

Family

ID=26709670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97954044T DK0960107T3 (da) 1996-12-24 1997-12-05 6-Thiosubstituerede paclitaxeler

Country Status (11)

Country Link
US (1) US5977386A (en:Method)
EP (1) EP0960107B1 (en:Method)
JP (1) JP2001507029A (en:Method)
AT (1) ATE225341T1 (en:Method)
AU (1) AU722684B2 (en:Method)
CA (1) CA2268774A1 (en:Method)
DE (1) DE69716135T2 (en:Method)
DK (1) DK0960107T3 (en:Method)
ES (1) ES2184149T3 (en:Method)
PT (1) PT960107E (en:Method)
WO (1) WO1998028288A1 (en:Method)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6362217B2 (en) 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
AU7007001A (en) 2000-06-22 2002-01-02 Nitromed Inc Nitrosated and nitrosylated taxanes, compositions and methods of use
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
DK2286795T3 (en) 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006089209A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
EP2010151B8 (en) 2006-03-22 2017-01-11 SynCore Biotechnology CO., LTD Treatment of triple receptor negative breast cancer
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
CN102040570B (zh) * 2009-10-14 2014-07-30 江苏先声药物研究有限公司 硫代紫杉烷类衍生物及其制备方法和用途
CA2878642C (en) 2012-07-19 2020-12-22 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
JP2016500058A (ja) 2012-11-12 2016-01-07 レッドウッド バイオサイエンス, インコーポレイテッド 化合物および抱合体を生成するための方法
DK3300745T3 (da) 2013-02-15 2019-11-04 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
HUE051255T2 (hu) 2014-02-19 2021-03-01 Aviv Therapeutics Inc Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére
PE20211798A1 (es) 2014-03-21 2021-09-13 Abbvie Inc Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
WO2017087723A1 (en) 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
DK3463308T3 (da) 2016-06-01 2022-01-31 Servier Ip Uk Ltd Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf
MX2018015271A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
CN109562168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
US12187801B2 (en) 2017-01-18 2025-01-07 Exuma Biotech Corp. Chimeric antigen receptors against AXL or ROR2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN111065623B9 (zh) 2017-05-24 2024-10-25 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
CN110003142A (zh) * 2018-01-04 2019-07-12 深圳福山生物科技有限公司 一种硒氰化合物及其用途
JP2021512110A (ja) 2018-01-31 2021-05-13 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California Methods of treating egfrviii expressing glioblastomas
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
US11660266B2 (en) 2018-04-11 2023-05-30 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
EP3823674A4 (en) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF
WO2020206033A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CN115023443A (zh) 2020-01-29 2022-09-06 肯乔克蒂生物技术股份有限公司 抗mdr1抗体及其用途
EP4161564A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
CA3182472A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
JP7747741B2 (ja) 2020-09-02 2025-10-01 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 抗abcc1抗体及びその使用
EP4244257A1 (en) 2020-11-13 2023-09-20 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
US12187810B2 (en) 2020-11-20 2025-01-07 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
JP3304088B2 (ja) * 1991-09-23 2002-07-22 フロリダ・ステイト・ユニバーシティ 10−デスアセトキシタキソール誘導体
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
ATE181551T1 (de) * 1992-04-17 1999-07-15 Abbott Lab Taxol-derivate
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
FR2697019B1 (fr) * 1992-10-15 1994-11-25 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2109861C (en) * 1992-12-04 1999-03-16 Shu-Hui Chen 6,7-modified paclitaxels
NZ261070A (en) * 1992-12-23 1997-10-24 Bristol Myers Squibb Co Oxazoline-substituted taxane derivatives and their preparation; intermediates
NO310238B1 (no) * 1992-12-24 2001-06-11 Bristol Myers Squibb Co Kjemiske forbindelser og farmasöytisk preparat samt anvendelse av slike preparater
ATE232854T1 (de) * 1993-03-05 2003-03-15 Univ Florida State Verfahren zur herstellung von 9-desoxotaxanen
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
DE69433146T2 (de) * 1993-06-11 2004-06-09 Pharmacia & Upjohn Co., Kalamazoo Delta 6,7-Taxol Derivate antineoplastische Verbindungen und diese enthaltende pharmazeutische Zusammenstellungen
US5767296A (en) * 1994-06-09 1998-06-16 Daiichi Pharmaceutical Co., Ltd. Deacetoxytaxol derivatives
CA2191224A1 (en) * 1994-06-28 1996-01-11 Pharmacia & Upjohn Company 7-ether-taxol analogs, antineoplastic use and pharmaceutical compositions containing them
CN1073105C (zh) * 1994-07-26 2001-10-17 因迪纳有限公司 具有抗肿瘤活性的半合成紫杉烷

Also Published As

Publication number Publication date
DE69716135D1 (en) 2002-11-07
CA2268774A1 (en) 1998-07-02
AU722684B2 (en) 2000-08-10
ES2184149T3 (es) 2003-04-01
EP0960107A4 (en:Method) 1999-12-01
AU5792298A (en) 1998-07-17
JP2001507029A (ja) 2001-05-29
EP0960107B1 (en) 2002-10-02
US5977386A (en) 1999-11-02
PT960107E (pt) 2003-02-28
EP0960107A1 (en) 1999-12-01
WO1998028288A1 (en) 1998-07-02
DE69716135T2 (de) 2003-06-05
ATE225341T1 (de) 2002-10-15

Similar Documents

Publication Publication Date Title
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
FI943749A0 (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ATE231872T1 (de) Thiazolopyrimidinderivate
FI964681A0 (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
MX9601994A (es) Profarmacos de derivados de paclitaxel.
SE9904377D0 (sv) Pharmaceutical combinations
SE9802937D0 (sv) Novel compounds
CA2152771A1 (en) 7-o-ethers of taxane derivatives
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
AU4558201A (en) Taxane anticancer agents
DE50004023D1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one
ECSP003536A (es) Derivados de rufomicina utiles como antibioticos